Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer
The World Journal of Men's Health
;
: 103-109, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-714396
ABSTRACT
Historically, testosterone and prostate cancer have been demonstrated to have a positive association leading providers to forgo testosterone replacement therapy (TRT) in men with concurrent histories of hypogonadism and prostate cancer. This paradigm has been gradually shifting with our evolving understanding of the relationship between testosterone and prostate cancer and the gaining popularity of the saturation model. Newer data suggests improved quality of life for men with hypogonadism after TRT leading to a more tempered view of the effects of this treatment and its risk in prostate cancer. As more reports emerge of TRT in men who have either undergone definitive treatment for prostate cancer or are on active surveillance, some providers see a role for TRT in these patients despite non-consensus in clinical guidelines. It is critical that we examine evidence currently available, while we await more rigorous data to emerge.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Próstata
/
Neoplasias de la Próstata
/
Calidad de Vida
/
Testosterona
/
Antígeno Prostático Específico
/
Hipogonadismo
/
Andrógenos
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
The World Journal of Men's Health
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS